阅读说明：本技术 用于预防及治疗癌因性疲乏的组合物及其用途 (Composition for preventing and treating cancer-induced fatigue and application thereof ) 是由 刘泳孝 金点溶 金珠英 朴宣奎 于 2013-08-30 设计创作，主要内容包括：本发明涉及一种用于预防及治疗癌因性疲乏的组合物及其用途,所述组合物含有人参提取物,所述人参提取物分别含有1～20重量％的皂苷Rh2和1～20重量％的皂苷Rg3。本发明的组合物可以为药物组合物或保健功能食品组合物,并且可以非常有效地用于预防及治疗癌因性疲乏,所述癌因性疲乏为由癌本身引起或与癌的治疗相关而产生的最具破坏性且普遍的副作用。(The invention relates to a composition for preventing and treating cancer-related fatigue and application thereof, wherein the composition contains ginseng extract, and the ginseng extract contains 1-20 wt% of saponin Rh2 and 1-20 wt% of saponin Rg3 respectively. The composition of the present invention may be a pharmaceutical composition or a health functional food composition, and may be very effectively used for preventing and treating cancer-induced fatigue, which is the most devastating and common side effect caused by cancer itself or associated with the treatment of cancer.)

1. Use of a pharmaceutical composition for the manufacture of a medicament for the prevention or treatment of cancer-related fatigue, wherein the prevention or treatment of cancer-related fatigue is the prevention or treatment of cancer cachexia,

the pharmaceutical composition comprises an extract of ginseng,

the ginseng extract contains 1-20 wt% of saponin Rh2 and 1-20 wt% of saponin Rg3 respectively.

2. The application of a health-care functional food composition in preparing health-care functional food for preventing or improving cancer-caused fatigue is characterized in that the prevention or improvement of cancer-caused fatigue is cancer cachexia prevention or improvement,

the health functional food composition comprises an extract of ginseng,

the ginseng extract contains 1-20 wt% of saponin Rh2 and 1-20 wt% of saponin Rg3 respectively.

Technical Field

The present invention relates to a composition for preventing and treating cancer-related fatigue, which is characterized in that the composition contains a novel processed ginseng powder or a processed ginseng extract in which a trace amount of ginsenoside ingredient is increased by preparing a saponin decomposition enzyme and then hydrolyzing the prepared saponin decomposition enzyme and an organic acid. The present invention provides a composition having an effect of ameliorating cancer-induced fatigue, which is the most severe of side effects caused by cancer itself or associated with the treatment of cancer.

Background

Cancer-related fatigue is one of the most frequently occurring side effects when or after cancer is treated. Cancer-related fatigue (CRF) is defined as "feeling of continuous and subjective fatigue (tiresome) associated with Cancer and Cancer treatment that hamper daily life and deteriorate the quality of life of Cancer patients" in the National Comprehensive Cancer Network (NCCN). Cancer-related fatigue cannot be relieved by rest and is not induced at one time by physical activity. From this point, it is possible to distinguish from ordinary fatigue.

Cancer-related side effects include the most negative effect of cancer-related fatigue on the quality of life of cancer patients, which limits daily life, because cancer-related fatigue is very severe, chronic, and painful, and is not relieved by rest.

It is reported that the incidence of cancer-induced fatigue in the treatment of cancer varies depending on the treatment method and time used, but almost all cancer patients experience it. That is, the incidence of cancer-induced fatigue in cancer patients who have not received anticancer therapy is about 75%, whereas the incidence of cancer-induced fatigue in cancer patients who have received chemotherapy or radiotherapy is higher. To the extent that patients experience cancer-related fatigue, overall, patients receiving bone marrow transplantation and chemotherapy exhibit more severe cancer-related fatigue than patients receiving adjuvant chemotherapy (adjuvant) without bone marrow transplantation, and patients receiving adjuvant chemotherapy often complain of cancer-related fatigue more frequently than patients receiving radiation therapy. (Ikjung, 2010)

Including cancers caused by fatigue and various side effects or symptoms (e.g., depression, restlessness, pain, nausea, vomiting, insomnia, anemia, etc.) caused during the treatment of cancer require excessive rest and result in muscle weakness, muscle atrophy, impaired muscle function and impaired cardiopulmonary function. Inactivity (inactivity) due to bed rest, etc., may further deteriorate the basic daily living ability of the patient.

The pharmacotherapy for cancer-related fatigue is mostly aimed at symptomatic effects more than approaching causes, and results in failure to solve problems such as a decrease in physical strength or a decline in muscle mass and muscle function that occur together in the course of treating cancer.

The main pharmacological activity of Modafinil (Modafinil), a drug associated with improvement of cancer-related fatigue, is promotion of wakefulness. Modafinil promotes wakefulness not only in mice (Touret et al, 1995; Edgar and Seidel, 1997), cats, dogs (Shelton et al, 1995) and non-human primates (Hernant et al, 1991), but also in models modeled as clinical situations such as sleep apnea syndrome (English bulldog's breathing model) (Panckeriet, 1996) and narcolepsy (narcolepsy) (Shelton et al, 1995). Modafinil is also described as a substance having activity in the central nervous system as a useful agent for the treatment of parkinson's disease (U.S. Pat. No. 5,180,745), the protection of brain tissue from blood deficiency (U.S. Pat. No. 5,391,576), the treatment of urinary and urinary incontinence (U.S. Pat. No. 5,401,776), and the treatment of sleep apnea syndrome and centrally-derived diseases.

Currently, clinical studies are conducted in which modafinil is administered together with Docetaxel (Docetaxel-Based Chemotherapy) to patients suffering from metastatic breast cancer and prostate cancer suffering from cancer-related fatigue, and Radiation Therapy (Radiation Therapy) is administered together to patients suffering from solid cancer suffering from cancer-related fatigue, thereby performing clinical studies as a cancer-related fatigue therapeutic agent (j.clin.30,2012).

The main functional component of ginseng is ginsenoside which is named as "ginsenosides" by distinguishing it among various saponins in the plant kingdom. The saponin in Ginseng radix component has anticancer, antiallergic and antiinflammatory effects, and also has pharmacological effects of inhibiting and tranquilizing central nervous system, relieving pain, improving memory, protecting liver injury, promoting protein and lipid synthesis, resisting diabetes and stress, promoting generation of antioxidant active substances, regulating immunity, inhibiting platelet aggregation, and resisting aging.

In addition, saponins such as ginsenosides Rb1, Rb2 and Rc, which are main components showing pharmacological effects of ginseng, are known. However, it is known that the components involved in the substantial anticancer effect, the inhibition of the metastasis of cancer cells, or the antiallergic effect are saponins such as compound k (comp k), ginsenoside Rh1, Rh2, Rg3, which are contained in ginseng in a very small amount.

Ginsenoside Rh2, which has been known as an effect of causing cancer fatigue, is known as a composition for preventing or treating causing cancer fatigue (chinese granted patent No. 101612159, 2011.08.31), and it has been reported that Rg3 is not dependent on the fatigue-reducing effect of a patient from which cancer cells are removed in terms of the amount used (Kou Xiao-ge et al, National medical frontiers of China, 2010, Abstract), but ginsenoside Rg3 has an anti-fatigue effect when administered into the nasal cavity (Wenyan et al, 2008). However, at present, there is no patent or research literature on the effect of cancer-related fatigue caused by the combination or content of the ginsenosides Rh2 and/or Rg 3.

Generally, pharmacotherapy for cancer-induced fatigue is different from general fatigue recovered by rest, and most cases aim at symptomatic effect rather than approach to cause, and it is impossible to solve problems such as physical strength reduction and deterioration of muscle mass and muscle function which occur together in the course of treating cancer. Recently, it has been reported that, for cancer patients receiving chemotherapy or radiotherapy, the most advantageous mechanisms for the occurrence of cancer-related fatigue are increased activity of pro-inflammatory cytokines and decreased synthesis of Glycogen (Glycogen) in muscle, etc.

In view of the above, the present inventors have demonstrated that a composition characterized by containing processed ginseng powder or processed ginseng extract in which trace amounts of ginsenoside components Rh2 and Rg3 are increased by hydrolysis using prepared saponin lyase and organic acid is very effective in preventing or treating cancer-induced fatigue, thereby completing the present invention.

Disclosure of Invention

Technical problem to be solved

The present inventors have found the fact that hydrolysis using the prepared saponin lyase and an organic acid after preparing the saponin lyase, so that trace amount of the ginsenoside component is increased to the processed ginseng powder or the processed ginseng extract, contributes to improvement of cancer-induced fatigue.

Accordingly, it is an object of the present invention to provide a processed ginseng powder or a processed ginseng extract composition in which the increase of the ginsenoside content in a trace amount effective for cancer-related fatigue is achieved by preparing a saponin decomposition enzyme and then hydrolyzing the prepared saponin decomposition enzyme and an organic acid.

Technical scheme

The present invention relates to a composition for preventing or treating cancer-related fatigue, which contains processed ginseng powder or processed ginseng extract in which the content of ginsenoside is increased by preparing saponin decomposition enzyme by the preparation method of korean patent No. 992800 and then hydrolyzing the prepared saponin decomposition enzyme and organic acid.

That is, the present invention relates to a pharmaceutical composition for preventing or treating cancer-induced fatigue, which comprises a ginseng extract prepared by the steps of:

(a) inoculating Aspergillus niger (Aspergillus niger) into a culture medium consisting of ginseng powder and wheat bran, (b) culturing the bacteria of the step (a), (c) refining the culture of the step (b) with an ultrafiltration membrane (ultrafiltration), (d) separating the enzyme from the refined product of the step (c), (e) adding the enzyme of the step (d) to ginseng powder, red ginseng powder, ginseng extract or red ginseng extract, (f) fermenting the additive of the step (e), (g) separating the fermented product of the step (f), (h) concentrating the supernatant of the step (g), (i) reacting the concentrate of the step (h) with one or more organic acids selected from acetic acid, lactic acid, citric acid, malic acid and tartaric acid, and (j) neutralizing the reactant of the step (i), Filtering, refining, concentrating and drying.

The composition of the invention is characterized by containing saponins Rh2 and Rg 3. The mixed composition of Rh2 and Rg3 has an excellent effect of improving cancer-induced fatigue induced by an anticancer agent, compared with a composition containing Rh2 or Rg3 alone, and the excellent effect tends to be higher.

Preferably, the content of the ginsenosides Rh2 and Rh 3 is 0.2-30 wt%, more preferably 0.5-30 wt%, and most preferably 1-20 wt%, respectively.

The processed ginseng powder or the processed ginseng extract in which the trace amount of ginsenoside increased by preparing the saponin lyase and then hydrolyzing the prepared saponin lyase and the organic acid is used together with the existing anticancer agent has the effect of improving cancer-induced fatigue induced by the anticancer agent.

The existing anticancer agents are equivalent to cisplatin, carboplatin, beradin, oxaliplatin, nedaplatin, doxorubicin, taxol, docetaxel, tamoxifen, cotutobel (Camtobell), fluorouracil (Adrucil), gleevec, etoposide, selectadine, ancepin, oxypheniral, jiangxian, 5-fluorouracil, leucovorin and the like.

It is preferable to use the novel processed ginseng powder or processed ginseng extract increased by preparing the saponin decomposition enzyme and then hydrolyzing the prepared saponin decomposition enzyme and the organic acid in combination with 0.1 to 1000 parts by weight of the trace ginsenoside component of the present invention based on 1 part by weight of the existing anticancer agent. When the content is within the above range, cancer-induced fatigue, which is a side effect caused by the anticancer agent, can be effectively improved.

The pharmaceutical composition for preventing or treating cancer-related fatigue, which is characterized by comprising processed ginseng powder or processed ginseng extract in which a trace amount of ginsenoside component is increased by preparing a saponin-decomposing enzyme and hydrolyzing the resultant saponin-decomposing enzyme and an organic acid, according to the present invention, may be formulated in various oral or non-oral administration forms as described below, but is not limited thereto.

The composition of the present invention, which is characterized by containing a novel processed ginseng powder or a processed ginseng extract in which a trace amount of ginsenoside components is increased by preparing a saponin-decomposing enzyme and then hydrolyzing the resultant saponin-decomposing enzyme and an organic acid, is useful for preventing or improving cancer-related fatigue, and can be prepared into health-assisting or health-care functional foods such as foods, beverages, and the like. In this case, when the composition of the present invention is used as a food additive, the composition of the present invention may be added in an amount of 0.01 to 30% by weight, preferably 0.1 to 10% by weight, based on the raw material. The amount of the active ingredient to be mixed may be appropriately determined depending on the purpose of use. However, when the composition is ingested for a long period of time for the purpose of health and hygiene or for the purpose of health regulation, the content may be less than the above range, and since there is no problem in safety, the active ingredient may be used in an amount of more than the above range. The composition characterized by containing processed ginseng powder or processed ginseng extract in which trace amount of ginsenoside component is increased by hydrolysis of the prepared saponin lyase and organic acid after the preparation of saponin lyase may be used together with other food or food ingredients, or may be used appropriately according to a conventional method.

Advantageous effects

The composition of the present invention is a composition containing a novel processed ginseng powder or a processed ginseng extract in which trace amounts of ginsenoside components are increased by preparing a saponin-decomposing enzyme and hydrolyzing the same with an organic acid, and is effective for preventing or treating cancer-induced fatigue.

The novel processed ginseng powder or processed ginseng extract composition containing increased trace amount of ginsenoside component by hydrolysis of the prepared saponin lyase and organic acid after the preparation of saponin lyase according to the present invention shows superior effect of preventing or treating cancer-induced fatigue, showing an upward trend, compared to the composition in which ginsenoside Rh2 or Rg3 is present alone, because it contains ginsenoside Rh2 or Rg3 in an increased amount at the same time.

In addition, the composition of the present invention shows excellent preventive and therapeutic or ameliorating effects on cancer-induced fatigue.

Best mode for carrying out the invention

The present invention relates to a composition for preventing or treating cancer-related fatigue, which comprises preparing a saponin decomposition enzyme by the preparation method of korean patent No. 992800, and hydrolyzing the prepared saponin decomposition enzyme and an organic acid so that a trace amount of ginsenoside components is increased to a novel processed ginseng powder or a processed ginseng extract.

The structure of the present invention will be described in more detail below with reference to specific examples thereof. However, the scope of the present invention is not limited to the description of the embodiments, and it is obvious to those skilled in the art that modifications may be made without departing from the technical spirit of the present invention, and the fact that such modifications fall within the scope of the present invention.

< comparative example 1: preparation of Ginseng powder >

200g of 6-year-old ginseng was hot-air dried and then pulverized to obtain 60g of ginseng powder.

< comparative example 2: preparation of Ginseng radix concentrated solution

After 200g of 6-year-old ginseng was hot-air dried, 70% alcohol of 1L was added, and after stirring and extraction at 70 ℃ for 8 hours, filtration and concentration were performed to obtain 50g of a ginseng concentrated solution.

< comparative example 3: preparation of concentrated Ginseng radix powder

After 200g of 6-year-old ginseng was hot-air dried, 70% ethanol 1L was added, and the mixture was stirred and extracted at 70 ℃ for 8 hours, followed by filtration, concentration and drying to obtain 30g of ginseng concentrated solution powder.

< comparative example 4: preparation of Red Ginseng

200g of 6-year-old ginseng was steam-evaporated at 98 ℃ for 1 hour, and then pulverized to obtain 40g of red ginseng powder.

< comparative example 5: preparation of Red Ginseng concentrate

200g of 6-year-old ginseng was evaporated to dryness with steam at 98 ℃ for 1 hour, then 70% ethanol 1L was added, and after stirring and extraction at 70 ℃ for 8 hours, filtration and concentration were carried out to obtain 30g of a concentrated solution of red ginseng.

< comparative example 6: preparation of Red Ginseng concentrate powder

200g of 6-year-old ginseng was evaporated to dryness with steam at 98 ℃ for 1 hour, then 70% ethanol 1L was added, and after stirring and extraction at 70 ℃ for 8 hours, filtration, concentration and drying were carried out to obtain 25g of red ginseng concentrate powder.

< comparative example 7: preparation of Ginseng radix powder + 0.2% Rh2+ 0.3% Rg3 >

99.5g of the ginseng powder of comparative example 1 was mixed with 0.2g of Rh2 and 0.3g of Rg 3.

< comparative example 8: preparation of Red Ginseng powder + 0.2% Rh2+ 0.3% Rg3 >

99.5g of the red ginseng powder of comparative example 4 was mixed with 0.2g of Rh2 and 0.3g of Rg 3.

< comparative example 9: preparation of Red Ginseng powder + 1% Rh2 >

99g of the red ginseng powder of comparative example 4 was mixed with 1g of Rh 2.

< comparative example 10: preparation of Red Ginseng powder + 1% Rg3 >

99g of the red ginseng powder of comparative example 4 was mixed with 1g of Rg 3.

< comparative example 11: preparation of Red Ginseng powder + 0.5% Rh2+ 0.5% Rg3 >

99g of the red ginseng powder of comparative example 4 was mixed with 0.5g of Rh2 and 0.5g of Rg 3.

< comparative example 12: preparation of modafinil

Modafinil was mixed in Phosphate Buffered Saline (PBS) at a concentration of 100mg/kg.b.w and administered orally in an amount of 100 μ l per day.

< example 1: preparation of processed Ginseng radix powder Using Ginseng radix powder >

Adding 250g of Ginseng radix powder, 750g of testa Tritici, sterilizing at 121 deg.C under 1.5 atm with high pressure steam sterilizer, adding 2L sterilized water into sterilized culture medium, mixing, inoculating Aspergillus niger suspension (5 × 10)⁵Spore/culture medium weight g), and cultured at 28 ℃ for 7 days, after the culture is finished, 0.02M sodium acetate buffer solution is added and mixed, the culture medium is filtered, the filtered culture solution is filtered and concentrated using an ultrafiltration membrane (100KDa or more) to obtain 60g of enzyme solution, 30g of enzyme solution is added to 200g of ginseng powder of comparative example 1, after 18 hours of culture at 28 ℃, alcohol is added to precipitate the enzyme, and the supernatant is concentrated, 250g of citric acid is added to 200g of the concentrate after 2L of purified water is added, and stirring is performed at 50 ℃ for 18 hours, after the reaction is finished, 70% alcohol is added, and filtration and concentration are performed to obtain 200g of processed ginseng powder.

< example 2: preparation of processed Ginseng radix concentrate Using Ginseng radix concentrate

Adding 250g of Ginseng radix powder, 750g of wheat bran, sterilizing with high pressure steam sterilizer at 121 deg.C and 1.5 atm, adding 2L sterilized water to the sterilized culture medium, mixing, inoculating Aspergillus niger suspension (5 × 10)⁵Spore/media weight g) and cultured at 28 ℃ for 7 days. After the culture was completed, 0.02M sodium acetate buffer solution was added and mixed, and the medium was filtered. Use ofThe filtered culture solution was filtered and concentrated with an ultrafiltration membrane (100kDa or more) to obtain 60g of an enzyme solution, 200g of the ginseng concentrate of comparative example 2 was added with 30g of the enzyme solution, and after culturing at 28 ℃ for 18 hours, alcohol was added to precipitate the enzyme, and the supernatant was concentrated, 200g of the concentrate was added with 2L g of purified water, 250g of citric acid was added, and stirring at 50 ℃ for 18 hours, after the reaction was completed, 70% alcohol was added, and filtration and concentration were performed to obtain 190g of a processed ginseng concentrate.

< example 3: preparation of processed Ginseng radix concentrate powder Using Ginseng radix concentrate powder >

Adding 250g of Ginseng radix powder, 750g of testa Tritici, sterilizing with high pressure steam sterilizer at 121 deg.C under 1.5 atm, adding 2L sterilized water into sterilized culture medium, mixing, inoculating Aspergillus niger suspension (5 × 10)⁵Spore/culture medium weight g), and cultured at 28 ℃ for 7 days, after the culture is completed, 0.02M sodium acetate buffer solution is added and mixed, the culture medium is filtered, the filtered culture solution is filtered and concentrated using an ultrafiltration membrane (100KDa or more) to obtain 60g of enzyme solution, 200g of ginseng concentrate powder of comparative example 3 is added with 30g of enzyme solution, cultured at 28 ℃ for 18 hours, added with alcohol to precipitate the enzyme, and the supernatant is concentrated, 200g of the concentrate is added with 2L of purified water, 250g of acetic acid is added, and stirred at 50 ℃ for 8 hours, after the reaction is completed, 70% alcohol is added, and filtration, concentration and drying are performed to obtain 195g of processed ginseng concentrate powder.

< example 4: preparation of processed Red Ginseng powder Using Red Ginseng powder >

Adding 250g of Ginseng radix powder, 750g of testa Tritici, sterilizing with high pressure steam sterilizer at 121 deg.C under 1.5 atm, adding 2L sterilized water into sterilized culture medium, mixing, inoculating Aspergillus niger suspension (5 × 10)⁵Spore/media weight g) and cultured at 28 ℃ for 7 days. After the culture was completed, 0.02M sodium acetate buffer solution was added and mixed, and the medium was filtered. Filtering with ultrafiltration membrane (above 100 kDa)200g of the red ginseng powder of comparative example 4 was added with 30g of the enzyme solution, cultured at 28 ℃ for 18 hours, then alcohol was added to precipitate the enzyme, and the supernatant was concentrated, 200g of the concentrate was added with 2L g of purified water, then 250g of acetic acid was added, stirred at 50 ℃ for 8 hours, after the reaction was completed, 70% alcohol was added, and filtration, concentration and drying were performed to obtain 195g of processed red ginseng powder.

< example 5: preparation of concentrated Ginseng radix Rubri solution by use of concentrated Ginseng radix Rubri solution

Adding 250g of Ginseng radix powder, 750g of testa Tritici, sterilizing with high pressure steam sterilizer at 121 deg.C under 1.5 atm, adding 2L sterilized water into sterilized culture medium, mixing, inoculating Aspergillus niger suspension (5 × 10)⁵Spore/culture medium weight g), and cultured at 28 ℃ for 7 days, after the completion of the culture, 0.02M sodium acetate buffer solution was added and mixed, the culture medium was filtered, the filtered culture solution was filtered and concentrated using an ultrafiltration membrane (100KDa or more) to obtain 60g of an enzyme solution, 200g of the red ginseng concentrate of comparative example 5 was added with 30g of the enzyme solution, cultured at 28 ℃ for 18 hours, added with alcohol to precipitate the enzyme, and the supernatant was concentrated, 200g of the concentrate was added with 2L of purified water, 250g of citric acid was added, and stirred at 50 ℃ for 18 hours, after the completion of the reaction, 70% alcohol was added, and filtered and concentrated to obtain 190g of a processed red ginseng concentrate.

< example 6: preparation of processed Red Ginseng concentrate powder Using Red Ginseng concentrate powder >

Adding 250g of Ginseng radix powder, 750g of testa Tritici, sterilizing with high pressure steam sterilizer at 121 deg.C under 1.5 atm, adding 2L sterilized water into sterilized culture medium, mixing, inoculating Aspergillus niger suspension (5 × 10)⁵Spore/media weight g) and cultured at 28 ℃ for 7 days. After the culture was completed, 0.02M sodium acetate buffer solution was added and mixed, and the medium was filtered. Filtering and concentrating the filtered culture solution with ultrafiltration membrane (above 100 KDa)60g of enzyme solution was obtained, 30g of the enzyme solution was added to 200g of the red ginseng concentrate powder of comparative example 6, and after incubation at 28 ℃ for 18 hours, alcohol was added to precipitate the enzyme, and the supernatant was concentrated, 200g of the concentrate was added with 2L of purified water, 250g of acetic acid was added, and stirring was performed at 50 ℃ for 8 hours, after the reaction was completed, 70% alcohol was added, and filtration, concentration and drying were performed, thereby obtaining 195g of processed red ginseng concentrate powder.

The following table 1 is a table showing the contents of the saponins Rh2 and Rg3 contained in the preparations of the examples and comparative examples of the present invention analyzed by the method disclosed in korean granted patent No. 992800. It was confirmed that a novel processed ginseng powder or a processed ginseng extract in which trace amounts of ginsenoside components were increased by hydrolysis of the prepared saponin-degrading enzyme and an organic acid after preparing a ginseng saponin-degrading enzyme corresponding to the ginseng powder and red ginseng powder of examples 1 to 6 of the present invention was increased in Rh2 and Rg3 content as compared with the ginseng powder and red ginseng powder which were reaction target substances thereof. Comparative examples 7 to 11 were prepared to compare the effect of improving cancer-induced fatigue by the following procedure. The steps are, as in the present embodiment, simply adding Rh2 and Rg3 to ginseng powder and red ginseng powder that have not been subjected to hydrolysis treatment with saponin lyase and organic acid, so that the Rh2 and Rg3 contents are the same as those of Rh2 and Rg3 in the present embodiment.

TABLE 1

< experimental example 1: effect of composition for ameliorating fatigue caused by cancer >

A6-week-old Balb/c-nu/nu female mouse supplied by east Co Ltd and having a body weight of 20 + -2 g was used as an experimental animal, and the experimental animal was incubated at a temperature of 23 + -1 ℃ and a relative humidity of 55 + -15% at 12-hour intervalsFeeding in dark animal feeding room, allowing mice to freely take in feed (Oriental Co., Ltd.) for one week, acclimating, and observing with naked eye for symptoms, and feeding HT-29(5 × 10)⁶Cell/mouse) cells were each transplanted in an amount of 100. mu.l under the flank of a one-week-acclimated Balb/c-nu/nu mouse, and then observed with the naked eye. When the size of the tumor reaches 150mm³The spontaneous exercise activity (Running wheel activity) and the forced exercise amount (Swimming test) were measured after the administration of the anticancer agent and the drug was completed, and the amount of synthesis of glycogen in muscle was homogenized on the final dissection day, and then analyzed by an enzyme linked immunosorbent assay kit (E L isacut).

Running wheel activity (Running distance is m/10 min)

Spontaneous exercise amount was measured by Running wheel activity (Cancer related fatigue, CRF) as a parameter (parameter). Is measured inRun for a total of 10 minutes on the Wheel (Wheel) and convert it to distance (meters).

Running distance ═ circumference (30cm × 3.14.14) × turns/10 min

Swimming test (Swimming test)

After warm water (23 ± 1 ℃) is filled in a transparent constant temperature water tank (500mm × 500mm × 400mm) capable of maintaining a certain temperature and water depth, Forced Swimming (FS) is performed, and after physical strength is judged to be exhausted, the total swimming time is recorded.

Calculation of the increase (%)

(average of treatment groups of examples or comparative examples-average of control group)/(average of blank group-average of control group) × 100

For all examples, comparative examples, and the like, after being prepared by diluting each volume in Phosphate Buffered Saline (PBS), forced oral administration was performed using an oral administration needle (sonde). The dose volume was calculated from the body weight measured on the day of administration such that the dose was 100. mu.l/20 g and the administration time of the test substance was uniformly 4 weeks, and the test substance was administered at a frequency of once a day at about 10 am, by mixing and diluting in phosphate buffered saline at a concentration of 100mg/kg body weight. The groups of experimental examples for evaluating the present invention are shown in table 2.

The significance test for all experimental examples described below was a comparison of p-values at a significance level of 0.05 by the T-test analysis method (Student's T-test).

#: p < 0.05 vs blank: p is less than 0.05 to the control group

# #: p < 0.01 vs blank set: p is less than 0.01 for the control group

# ##: p < 0.001 vs blank set: p is less than 0.001 for the control group

TABLE 2

Table 3 below shows the results of comparative evaluation of spontaneous exercise amount due to cancer by running for 10 minutes after 4 weeks in the animal model of xenograft HT-29 large intestine cancer cell line by combined administration of examples and comparative example, and Table 4 shows the results of comparative evaluation of forced exercise amount due to cancer by swimming time, as the results of the experimental example 1. After preparing the ginseng saponin hydrolase for the ginseng powder and red ginseng powder corresponding to examples 1 to 6 of the present invention, the processed ginseng powder or processed ginseng extract in which a trace amount of ginsenoside component is increased shows an increase rate of spontaneous exercise amount of 62.6 to 96.2% and an increase rate of forced exercise amount of 63.0 to 98.0% by hydrolysis of the prepared saponin hydrolase and organic acid, and shows an excellent increase rate of exercise amount due to improvement of cancer-induced fatigue compared to the increase rate of spontaneous exercise amount and forced exercise amount of 3.2 to 18.8% shown by the ginseng powder and red ginseng powder corresponding to the reaction object substance of examples 1 to 6 of the present invention. In addition, the processed ginseng or the processed ginseng extract of examples 1 to 6 of the present invention shows an excellent exercise amount increase rate due to improvement of cancer-induced fatigue compared to the exercise amount increase rates of 20.8 to 30.6% for spontaneous exercise amount and forced exercise amount due to cancer of comparative examples 7 and 8 prepared by adding Rh2 and Rg3 to the ginseng powder and the red ginseng powder of comparative examples 1 and 4 by increasing the contents of Rh2 and Rg3 by 0.2 wt% and 0.3 wt%, respectively, as in example 1, and thus it can be understood that the exercise amount increase effect due to improvement of cancer-induced fatigue of the processed ginseng or the processed ginseng extract of the present invention is enhanced by the action of other effective components than Rh2 and Rg 3. In addition, comparative examples 9 to 11 are compositions prepared by further mixing 1g of Rh2, 1g of Rg3, and (0.5g of Rh2+0.5g of Rg3) with 99g of red ginseng powder, respectively, and when comparative example 11(0.5 wt% of Rh2+0.5 wt% of Rg3) is administered, superior therapeutic effects on cancer-related fatigue are exhibited as compared with comparative example 9 (containing 1 wt% of Rh2) and comparative example 10 (containing 1 wt% of Rg 3). Therefore, it was confirmed that the effect of ameliorating cancer-related fatigue or treating cancer tends to be higher when Rh2 or Rg3 is administered together than when Rh2 or Rg3 is administered alone.

TABLE 3

TABLE 4

< experimental example 2: effect of composition for ameliorating fatigue caused by anticancer agent >

Evaluation was performed under the same conditions as in example 1, but the evaluation was made on all of examples, comparative examples, and the like under the conditions of treatment with an anticancer agent. 5-Fluorouracil (5-FU) was used as an anticancer agent, and was treated 3 times per week at a concentration of 30 mg/kg. The groups used to evaluate the present invention are shown in table 5.

TABLE 5

Table 6 below shows the results of experiment example 2, in which the amounts of glycogen synthesis in muscle obtained from the hind leg thigh were compared on the final dissection day after 4 weeks of combined administration of an anticancer agent and each of examples and comparative examples in an animal model of a xenograft HT-29 large intestine cancer cell line. As a result, the amount of glycogen synthesized in the xenograft group in which colorectal cancer was xenografted was reduced by 39.2% as compared with the blank group, and the control group to which the anticancer agent was administered was also reduced by 51.4% as compared with the blank group. However, as a result of carrying out the treatment with the anticancer agent and the administration of examples 1 to 6 together, it was confirmed that the amount of glycogen synthesized was significantly increased as compared with the control group to which the anticancer agent was administered, and the group to which comparative example 12 (modafinil) was jointly administered did not change much as compared with the examples and the like. The increase rates of glycogen synthesis amounts in examples and comparative examples are shown in table 6.

TABLE 6

< experimental example 3: effect of composition for improving fatigue caused by radiation treatment >

Evaluation was performed under the same conditions as in example 1, but the evaluation was made on each of examples, comparative examples, and the like under the conditions of irradiation treatment. Treatment was 3 times per week with 10 Gy. The groups used to evaluate the present invention are shown in table 7.

TABLE 7

Table 8 below shows the results of experimental example 3, in which the amounts of glycogen synthesis in muscle obtained from the hind leg thigh were compared on the final dissection day after 4 weeks of combined irradiation with the combined administration of radiation and each of examples and comparative examples in an animal model in which an HT-29 large intestine cancer cell line was xenografted. As a result, the amount of glycogen synthesized in the xenografted group obtained by xenografting colorectal cancer was reduced by 36.5% as compared with the blank group, and the amount of glycogen synthesized in the control group subjected to radiation treatment was reduced by 51.4% as compared with the blank group. However, as a result of the combined treatment of the irradiation treatment and examples 1 to 6, it was confirmed that the amount of glycogen synthesized was significantly increased as compared with the control group subjected to the irradiation treatment, and the groups to which comparative examples 1, 4, 7, 9, 10, 11, and 12 (modafinil) were administered in combination did not change much as compared with examples and the like. The increase rates of glycogen synthesis amounts in examples and comparative examples are shown in table 8.

TABLE 8